Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3

AIDS

Volumn 25, Issue 15, 2011, Pages 1915-1919

  Chung, Michael H ^a   McKenzie, Kevin P ^a   Richardson, Barbra A ^a,b   John Stewart, Grace C ^a   Coombs, Robert W ^a   De Vuyst, Hugo ^c   Njoroge, Julia W ^a   Nyongesa Malava, Evans ^a   Sakr, Samah R ^d   Mugo, Nelly R ^a,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d Internal Medicine and Critical care Department   (Kenya)

^e KENYATTA NATIONAL HOSPITAL   (Kenya)

Author keywords

Africa; antiretroviral therapy; cervical intraepithelial neoplasia; cryotherapy; HIV 1; shedding

Indexed keywords

EFAVIRENZ; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; CRYOTHERAPY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS SHEDDING;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; CRYOTHERAPY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS; VIRUS SHEDDING;

EID: 80052925174     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834a3654     Document Type: Article

References (20)

1. Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet 1999; 353:869-873.
2. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005; 294:2173-2181. (Pubitemid 41571134)
3. Gaffikin L, Blumenthal PD, Emerson M, Limpaphayom K. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet 2003; 361:814-820. (Pubitemid 36331843)
4. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis 2007; 45:510-513. (Pubitemid 47204472)
5. Wright TC Jr, Subbarao S, Ellerbrock TV, Lennox JL, Evans-Strickfaden T, Smith DG, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 2001; 184:279-285. (Pubitemid 32206972)
6. Kreiss J, Willerford DM, Hensel M, Emonyi W, Plummer F, Ndinya-Achola J, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994; 170:1597-1601. (Pubitemid 24369926)
7. McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105-110. (Pubitemid 32055785)
8. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al. Genital HIV-1 RNA levels predict risk of heterosexual HIV-1 transmission. 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011.
9. Chung MH, McKenzie K, De Vuyst H, Pamnani R, Rana F, Njoroge J, et al. Comparing visual inspection with acetic acid, high-risk HPV testing, and PAP smear to colposcopic biopsy among HIVR women. 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011.
10. Chung MH, Drake AL, Richardson BA, Reddy A, Thiga J, Sakr SR, et al. Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 2009; 7:441-446.
11. John GC, Sheppard H, Mbori-Ngacha D, Nduati R, Maron D, Reiner M, et al. Comparison of techniques for HIV-1 RNA detection and quantitation in cervicovaginal secretions. J Ac-quir Immune Defic Syndr 2001; 26:170-175. (Pubitemid 32224189)
12. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-1808.
13. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-1508. (Pubitemid 351411987)
14. Graham SM, Holte SE, Peshu NM, Richardson BA, Panteleeff DD, Jaoko WG, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-507.
15. Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remolli-no C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421. (Pubitemid 30182438)
16. Gitau RW, Graham SM, Masese LN, Overbaugh J, Chohan V, Peshu N, et al. Effect of acquisition and treatment of cervical infections on HIV-1 shedding in women on antiretroviral therapy. AIDS 2010; 24:2733-2737.
17. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mudenda V, Hicks ML, Vermund SH, et al. Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS 2009; 23:N1-5.
18. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sulli-van MJ, et al., Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
19. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001; 183:206-212. (Pubitemid 32066020)
20. Lehman DA, Chung MH, John-Stewart GC, Richardson BA, Kiarie JN, Kinuthia J, et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 2008; 22:1475-1485.